BACKGROUND: The aim of the present analysis was to retrospectively evaluate outcomes in patients with cutaneous angiosarcoma of the face/scalp treated curatively with surgery, radiation therapy (RT), or a combination of surgery and RT. METHODS: In all, 70 patients with nonmetastatic angiosarcoma underwent surgery, RT, or combined-modality therapy. Of these, 20 patients (29%) were treated with surgery alone, 27 patients (39%) with RT alone, and 23 patients (33%) with combined-modality therapy; 44 patients received chemotherapy, either neoadjuvantly or adjuvantly or both. RESULTS: Median follow-up was 2.1 years. The overall survival (OS) rate was 43% at 5 years, and disease-specific survival (DSS) was 46% at 5 years. Tumor size > 5 cm and satellitosis were prognostic for inferior OS and DSS. Combined-modality therapy (vs surgery alone or RT alone) was associated with improved OS, DSS, and local control. CONCLUSIONS: Primary local therapy with combined-modality therapy was associated with improved local control, OS, and DSS for patients with angiosarcoma of the face/scalp.
BACKGROUND: The aim of the present analysis was to retrospectively evaluate outcomes in patients with cutaneous angiosarcoma of the face/scalp treated curatively with surgery, radiation therapy (RT), or a combination of surgery and RT. METHODS: In all, 70 patients with nonmetastatic angiosarcoma underwent surgery, RT, or combined-modality therapy. Of these, 20 patients (29%) were treated with surgery alone, 27 patients (39%) with RT alone, and 23 patients (33%) with combined-modality therapy; 44 patients received chemotherapy, either neoadjuvantly or adjuvantly or both. RESULTS: Median follow-up was 2.1 years. The overall survival (OS) rate was 43% at 5 years, and disease-specific survival (DSS) was 46% at 5 years. Tumor size > 5 cm and satellitosis were prognostic for inferior OS and DSS. Combined-modality therapy (vs surgery alone or RT alone) was associated with improved OS, DSS, and local control. CONCLUSIONS: Primary local therapy with combined-modality therapy was associated with improved local control, OS, and DSS for patients with angiosarcoma of the face/scalp.
Authors: Alexandra Buschmann; Marcus Lehnhardt; Nidal Toman; Peter Preiler; M Sedigh Salakdeh; Thomas Muehlberger Journal: Ann Plast Surg Date: 2008-10 Impact factor: 1.539
Authors: Jon R Ward; Steven J Feigenberg; Nancy Price Mendenhall; Robert B Marcus; William M Mendenhall Journal: Head Neck Date: 2003-10 Impact factor: 3.147
Authors: Richard J Cassidy; Jeffrey M Switchenko; Melinda L Yushak; Nicholas Madden; Mohammad K Khan; David K Monson; Jonathan J Beitler; Jerome C Landry; Karen D Godette; Theresa W Gillespie; Kirtesh R Patel Journal: Surg Oncol Date: 2018-09-13 Impact factor: 3.279
Authors: K Ogawa; K Takahashi; Y Asato; Y Yamamoto; K Taira; S Matori; S Iraha; N Yagi; A Yogi; S Haranaga; J Fujita; H Uezato; S Murayama Journal: Br J Radiol Date: 2012-07-17 Impact factor: 3.039
Authors: Massimo Di Battista; Mark R Darling; Edgar Scrivener; Richard Stapleford; Bret Wehrli; Christina McCord Journal: Head Neck Pathol Date: 2020-02-05
Authors: Sun Young Moon; Dong Hyuk Eun; Yong Hyun Jang; Seok-Jong Lee; Do Won Kim; Weon Ju Lee Journal: Ann Dermatol Date: 2017-10-30 Impact factor: 1.444
Authors: Matthew C Perez; Tapan A Padhya; Jane L Messina; Ryan S Jackson; Ricardo J Gonzalez; Marilyn M Bui; G Douglas Letson; C W Cruse; Robert S Lavey; David Cheong; Meghan R Forster; William J Fulp; Vernon K Sondak; Jonathan S Zager Journal: Ann Surg Oncol Date: 2013-07-09 Impact factor: 5.344
Authors: Darya Buehler; Stephanie R Rice; John S Moody; Patrick Rush; Gholam-Reza Hafez; Steven Attia; B Jack Longley; Kevin R Kozak Journal: Am J Clin Oncol Date: 2014-10 Impact factor: 2.339